Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.46 |
| ▸ | MTHFD2 | P13995 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8233741 | 0.84 | KCNK3 (0.47) | GRM5LMNANPC1RAB9APTGDR2 | |
| SCHEMBL23387867 | 0.82 | SHMT2 (0.42) | TSHRHPGDLMNANPC1RAB9A | |
| SCHEMBL4112315 | 0.79 | AR (0.46) | TSHRGRM5NPC1RAB9AHSP90AA1 | |
| SCHEMBL17232774 | 0.79 | SHMT2 (0.54) | TSHRHPGDLMNANPC1RAB9A | |
| SCHEMBL4259746 | 0.73 | LMNA (0.50) | TSHRHPGDLMNANPC1RAB9A | |
| SCHEMBL4265115 | 0.73 | NPC1 (0.47) | TSHRHPGDLMNANPC1RAB9A | |
| SCHEMBL14591322 | 0.72 | PTGDR2 (0.58) | HPGDLMNAPTGDR2MTHFD2CYP2C9 | |
| SCHEMBL16217172 | 0.72 | ESR2 (0.43) | HSP90AA1 | |
| SCHEMBL11090704 | 0.72 | PTGS1 (0.50) | GRM5HPGDPTGDR2MTHFD2CYP2C9 | |
| SCHEMBL5527334 | 0.72 | HPGD (0.46) | TSHRHPGDLMNANPC1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | GRUNENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007079957-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075978-A1 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS | PCCA, PPARA, PTGES | TSHR 3169/4885GRM5 866/4885HPGD 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.